Andrew R. Branagan

5.4k total citations · 1 hit paper
121 papers, 3.1k citations indexed

About

Andrew R. Branagan is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Andrew R. Branagan has authored 121 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Genetics, 53 papers in Pathology and Forensic Medicine and 45 papers in Hematology. Recurrent topics in Andrew R. Branagan's work include Chronic Lymphocytic Leukemia Research (90 papers), Lymphoma Diagnosis and Treatment (51 papers) and Multiple Myeloma Research and Treatments (25 papers). Andrew R. Branagan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (90 papers), Lymphoma Diagnosis and Treatment (51 papers) and Multiple Myeloma Research and Treatments (25 papers). Andrew R. Branagan collaborates with scholars based in United States, France and Greece. Andrew R. Branagan's co-authors include Steven P. Treon, Zachary R. Hunter, Kenneth C. Anderson, Meletios Α. Dimopoulos, Roger G. Owen, Ayad Al‐Katib, Philip R. Greipp, Jesús F. San Miguel, Enrica Morra and Gerassimos A. Pangalis and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Andrew R. Branagan

106 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

2003 621 citations Steven P. Treon, Andrew R. Branagan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew R. Branagan United States	25	2.3k	1.8k	1.1k	993	532	121	3.1k
Lawrence D. Piro United States	27	1.7k 0.7×	1.3k 0.7×	846 0.8×	511 0.5×	921 1.7×	59	2.8k
Francesca Romana Mauro Italy	31	2.4k 1.0×	1.7k 0.9×	1.3k 1.2×	739 0.7×	630 1.2×	157	3.3k
Piers Blombery Australia	26	890 0.4×	606 0.3×	653 0.6×	749 0.8×	675 1.3×	122	2.4k
Monica Bocchia Italy	28	1.1k 0.5×	850 0.5×	964 0.9×	1.3k 1.3×	1.0k 1.9×	179	2.9k
Charles Herbaux France	23	1.1k 0.5×	1.2k 0.6×	591 0.5×	460 0.5×	675 1.3×	111	1.9k
Carolyn Owen Canada	21	2.1k 0.9×	1.8k 1.0×	782 0.7×	989 1.0×	702 1.3×	99	3.1k
Andrzej Hellmann Poland	23	1.8k 0.8×	1.3k 0.7×	711 0.6×	1.5k 1.5×	589 1.1×	58	3.1k
Danelle F. James United States	31	3.0k 1.3×	2.4k 1.3×	1.5k 1.4×	1.2k 1.2×	620 1.2×	101	3.9k
Ellen D. Remstein United States	26	973 0.4×	1.5k 0.8×	571 0.5×	807 0.8×	985 1.9×	40	2.7k
Jacqueline C. Barrientos United States	27	2.3k 1.0×	1.9k 1.1×	995 0.9×	672 0.7×	630 1.2×	178	2.9k

Countries citing papers authored by Andrew R. Branagan

Since Specialization

Citations

This map shows the geographic impact of Andrew R. Branagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew R. Branagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew R. Branagan more than expected).

Fields of papers citing papers by Andrew R. Branagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew R. Branagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew R. Branagan. The network helps show where Andrew R. Branagan may publish in the future.

Co-authorship network of co-authors of Andrew R. Branagan

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew R. Branagan. A scholar is included among the top collaborators of Andrew R. Branagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew R. Branagan. Andrew R. Branagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Castillo, Jorge J., Francesco Autore, Neil L. Berinstein, et al.. (2025). Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. Seminars in Hematology. 62(2). 113–119.

Choa, Ruth, Kevin C. Miller, Samuel Han, et al.. (2025). Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma. 1(3). 100015–100015.

Sarosiek, Shayna, Andrew R. Branagan, Simone Ferrero, et al.. (2025). Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia. Seminars in Hematology. 62(2). 85–89.

Tsakmaklis, Nickolas, Maria Luisa Guerrera, Gottfried von Keudell, et al.. (2025). Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications. Blood. 146(Supplement 1). 3577–3577.

Han, Samuel, Andrew R. Branagan, Elizabeth O’Donnell, et al.. (2025). Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury. Blood Advances. 9(13). 3129–3135. 2 indexed citations

Castillo, Jorge J., Gottfried von Keudell, Andrew R. Branagan, et al.. (2025). High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study. Blood. 146(Supplement 1). 225–225.

Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2025). Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Advances. 9(12). 3026–3030. 1 indexed citations

Castillo, Jorge J., Shayna Sarosiek, Andrew R. Branagan, et al.. (2024). A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis. Blood. 144(Supplement 1). 3011–3011. 5 indexed citations

Nakamoto-Matsubara, Rie, Valentina Nardi, Nora Horick, et al.. (2024). Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer Journal. 14(1). 224–224. 2 indexed citations

10.

Castillo, Jorge J., Shayna Sarosiek, Andrew R. Branagan, et al.. (2024). Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia. Blood Advances. 8(9). 2133–2137. 1 indexed citations

11.

Castillo, Jorge J., et al.. (2024). P-290 Ibrutinib Plus Rituximab Versus Ibrutinib Monotherapy in Patients With Waldenström Macroglobulinemia: A Pooled Analysis of Three Prospective Studies. Clinical Lymphoma Myeloma & Leukemia. 24. S203–S203. 2 indexed citations

12.

Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2024). OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S4–S5. 1 indexed citations

13.

O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2023). A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 142(Supplement 1). 4671–4671. 2 indexed citations

14.

Guerrera, Maria Luisa, Zachary R. Hunter, Nickolas Tsakmaklis, et al.. (2023). Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth. Blood. 142(Supplement 1). 3303–3303. 1 indexed citations

15.

Verma, Rakesh, Andrew R. Branagan, Mina L. Xu, et al.. (2021). Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia. 35(11). 3319–3323. 1 indexed citations

16.

Treon, Steven P., Christian Buske, Sheeba K. Thomas, et al.. (2021). Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood. 138(Supplement 1). 1362–1362. 11 indexed citations

17.

Branagan, Andrew R., Eamon Duffy, Connor Foster, et al.. (2017). Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders. Blood. 130. 438–438. 4 indexed citations

18.

Leleu, Xavier, Kelly O’Connor, Allen W. Ho, et al.. (2006). Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. American Journal of Hematology. 82(1). 83–84. 27 indexed citations

19.

Ho, Allen W., Xavier Leleu, Evdoxia Hatjiharissi, et al.. (2005). A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia.. Blood. 106(11). 4701–4701. 4 indexed citations

20.

Treon, Steven P., Zachary R. Hunter, Jeffrey Matous, et al.. (2005). Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.. Blood. 106(11). 490–490. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact